|
DE60222396T2
(de)
*
|
2001-03-29 |
2008-05-15 |
Eli Lilly And Co., Indianapolis |
N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
|
|
EP1411925A1
(en)
*
|
2001-08-03 |
2004-04-28 |
PHARMACIA & UPJOHN COMPANY |
5-arylsulfonyl indoles having 5-ht6 receptor affinity
|
|
BR0312176A
(pt)
|
2002-06-21 |
2005-04-05 |
Suven Life Sciences Ltd |
Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
|
|
WO2004007456A1
(en)
*
|
2002-07-17 |
2004-01-22 |
Lek Pharmaceuticals D.D. |
Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
|
|
KR101025633B1
(ko)
|
2002-09-19 |
2011-03-30 |
일라이 릴리 앤드 캄파니 |
오피오이드 수용체 안타고니스트로서의 디아릴 에테르
|
|
EP1572647B1
(en)
*
|
2002-12-20 |
2016-09-21 |
Basf Se |
Synthesis of amines and intermediates for the synthesis thereof
|
|
ATE406360T1
(de)
|
2003-03-07 |
2008-09-15 |
Lilly Co Eli |
Antagonisten der opioidrezeptoren
|
|
EP1613597B1
(en)
|
2003-03-07 |
2007-11-07 |
Eli Lilly and Company |
6-substituted nicotinamide derivatives as opioid receptor antagonists
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
PT1558582E
(pt)
|
2003-07-22 |
2006-05-31 |
Arena Pharm Inc |
Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
|
|
ES2390459T3
(es)
|
2003-12-22 |
2012-11-13 |
Eli Lilly And Company |
Antagonistas de receptores de opioides
|
|
DE602005022572D1
(de)
|
2004-03-12 |
2010-09-09 |
Lilly Co Eli |
Antagonisten des opioidrezeptors
|
|
EP1735268B1
(en)
|
2004-03-15 |
2012-02-15 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
DE602005012380D1
(de)
|
2004-03-15 |
2009-03-05 |
Lilly Co Eli |
4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
|
|
RS56037B1
(sr)
|
2004-06-24 |
2017-09-29 |
Vertex Pharma |
Modulatori atp-vezujućih kasetnih transportera
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
ATE474833T1
(de)
*
|
2004-09-22 |
2010-08-15 |
Janssen Pharmaceutica Nv |
Inhibitoren der wechselwirkung zwischen mdm2 und p53
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
EP3219705B1
(en)
|
2005-12-28 |
2020-03-11 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CN101351707B
(zh)
*
|
2005-12-28 |
2014-03-26 |
积水医疗株式会社 |
凝集测量用试剂以及凝集测量方法
|
|
EP1973905A4
(en)
*
|
2006-01-06 |
2010-12-08 |
Astrazeneca Ab |
COMPOUNDS
|
|
JP5162574B2
(ja)
|
2006-03-22 |
2013-03-13 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｍｄｍ２及びｐ５３間の相互作用のインヒビターとしての環式アルキルアミン誘導体
|
|
JP5385125B2
(ja)
*
|
2006-03-22 |
2014-01-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ＭＤＭ２とｐ５３の間の相互作用の阻害剤
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
US8017785B2
(en)
|
2006-05-09 |
2011-09-13 |
Astrazeneca Ab |
Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
ES2534899T3
(es)
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
|
JO2704B1
(en)
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
US20090093513A1
(en)
*
|
2007-10-09 |
2009-04-09 |
Hamann Mark T |
Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
|
|
CA2706651A1
(en)
*
|
2007-12-04 |
2009-06-11 |
Merck Sharp & Dohme Corp. |
Tryptamine sulfonamides as 5-ht6 antagonists
|
|
EP2508177A1
(en)
|
2007-12-12 |
2012-10-10 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
EP2254865A1
(en)
*
|
2008-02-11 |
2010-12-01 |
Organix, Inc. |
Indole compounds and methods of use thereof
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
US8541442B2
(en)
|
2009-02-04 |
2013-09-24 |
Janssen Pharmaceutica N.V. |
Indole derivatives as anticancer agents
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
PL2408750T3
(pl)
|
2009-03-20 |
2016-02-29 |
Vertex Pharma |
Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
|
|
EP2464227A4
(en)
*
|
2009-08-10 |
2013-02-20 |
Galenea Corp |
COMPOUNDS AND METHODS OF USE
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
*
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
WO2014165701A1
(en)
*
|
2013-04-03 |
2014-10-09 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
薬学的組成物およびその投与
|
|
CA2866910A1
(en)
*
|
2012-03-20 |
2013-09-26 |
Adamed Sp. Z O.O. |
Sulphonamide derivatives of benzylamine for the treatment of cns diseases
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
*
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
CN107250113B
(zh)
|
2014-10-07 |
2019-03-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节蛋白的调节剂的共晶
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
WO2016091997A1
(en)
|
2014-12-12 |
2016-06-16 |
H. Lundbeck A/S |
A process for the manufacture of idalopirdine
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
CN108271369A
(zh)
|
2015-10-23 |
2018-07-10 |
法尔玛赞公司 |
用于制备色胺及其衍生物的新工艺
|
|
US9975850B2
(en)
|
2016-04-08 |
2018-05-22 |
H. Lundbeck A/S |
Process for the manufacture of idalopirdine via hydrogenation of an imine
|
|
CN118806909A
(zh)
*
|
2016-04-26 |
2024-10-22 |
H.隆德贝克有限公司 |
乙酰胆碱酯酶抑制剂和艾达鲁吡啶用于减少帕金森氏病患者跌倒的用途
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
MX385719B
(es)
|
2017-05-24 |
2025-03-18 |
H Lundbeck As |
Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4
|
|
CA3185336A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
|
|
WO2020179859A1
(ja)
|
2019-03-06 |
2020-09-10 |
第一三共株式会社 |
ピロロピラゾール誘導体
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
AU2021268204A1
(en)
|
2020-05-08 |
2022-12-08 |
Psilera Inc. |
Novel compositions of matter and pharmaceutical compositions
|
|
KR20240096817A
(ko)
|
2020-05-19 |
2024-06-26 |
사이빈 아이알엘 리미티드 |
중수소화된 트립타민 유도체 및 사용 방법
|
|
EP4208446A4
(en)
*
|
2020-09-02 |
2024-10-30 |
Enveric Biosciences Canada Inc. |
PSILOCYBIN NITROGEN DERIVATIVES AND ASSOCIATED USE FOR THE MODULATION OF THE 5-HT2A RECEPTOR AND FOR THE TREATMENT OF A PSYCHIATRIC DISORDER
|
|
EP4213843A4
(en)
*
|
2020-09-17 |
2024-09-11 |
Merck Sharp & Dohme LLC |
MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
|
|
EP4291549A4
(en)
*
|
2021-02-12 |
2025-01-22 |
Enveric Biosciences Canada Inc. |
MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE
|
|
AU2022229037A1
(en)
*
|
2021-03-02 |
2023-09-28 |
Mindset Pharma Inc. |
Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
|
|
CA3217737A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Jason WALLACH |
Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
|
|
IL308816A
(en)
|
2021-05-25 |
2024-01-01 |
Atai Therapeutics Inc |
New n,n-dimethyltryptamine salts and crystalline salt forms
|
|
BR112023025599A2
(pt)
*
|
2021-06-08 |
2024-02-20 |
Entheogenix Biosciences Inc |
Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
|
|
MX2023014620A
(es)
|
2021-06-09 |
2024-01-30 |
Atai Therapeutics Inc |
Nuevos profarmacos y conjugados de dimetiltriptamina.
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
EP4457203A4
(en)
|
2021-12-27 |
2025-12-17 |
Atai Therapeutics Inc |
AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
|
|
JP2024545787A
(ja)
|
2021-12-30 |
2024-12-11 |
アタイ セラピューティクス， インコーポレイテッド |
一酸化窒素送達剤としてのジメチルトリプタミン類似体
|
|
US12065404B2
(en)
|
2022-03-18 |
2024-08-20 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
EP4704822A1
(en)
|
2023-05-01 |
2026-03-11 |
ATAI Therapeutics, Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
WO2025160304A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|